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To examine safety and efﬁcacy of bandage soft contact lenses (BSCLs) for ocular chronic graft-versus host
disease (GVHD), we conducted a phase II clinical trial. Extended-wear BSCLs were applied under daily topical
antibiotic prophylaxis. Patients completed standardized symptom questionnaires at enrollment and at
2 weeks, 4 weeks, and 3 months afterward. Ophthalmologic assessment was performed at enrollment, at
2 weeks, and afterward as medically needed. Assessments at follow-up were compared with baseline by
paired t-test. Nineteen patients with ocular GVHD who remained symptomatic despite conventional treat-
ments were studied. The mean Lee eye subscale score was 75.4 at enrollment and improved signiﬁcantly to
63.2 at 2 weeks (P ¼ .01), to 61.8 at 4 weeks (P ¼ .005), and to 56.3 at 3 months (P ¼ .02). The ocular surface
disease index score and 11-point eye symptom ratings also improved signiﬁcantly. According to the Lee eye
subscale, clinically meaningful improvement was observed in 9 patients (47%) at 2 weeks, in 11 patients (58%)
at 4 weeks, and in 9 patients (47%) at 3 months. Visual acuity improved signiﬁcantly at 2 weeks compared
with enrollment values. Based on slit lamp exam at 2 weeks, punctate epithelial erosions improved in 58% of
the patients, showed stability in 16%, and worsened in 5%. No corneal ulceration or ocular infection occurred.
BSCLs are a widely available, safe, and effective treatment option that improves manifestations of ocular
GVHD in approximately 50% of patients. This study was registered at www.clinicaltrials.gov as NCT01616056.
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Allogeneic hematopoietic cell transplantation is a curative
treatment for many hematologic malignancies and nonma-
lignant disorders, but chronic graft-versus-host disease
(GVHD) is the leading cause of late morbidity in transplant
recipients, compromising both quality of life and function
[1]. Ocular GVHD occurs in 40% to 60% of patients with
chronic GVHD [2-9]. Ocular manifestations range from mild
conjunctivitis and keratoconjunctivitis sicca to severe cica-
tricial conjunctivitis and corneal perforation [10]. Severe
photophobia, eye pain, and loss of vision caused by ocular
GVHD interferes signiﬁcantly with patients’ activities of daily
living. Superﬁcial punctate keratitis and ﬁlamentary keratitis
are the major components that cause ocular symptoms in
patients with ocular GVHD. In a prospective multicenter
observational cohort of patients with chronic GVHD, severityedgments on page 2007.
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ty for Blood and Marrow Transplantation.and severe in 6% [7].
Systemic immunosuppressive therapy alone often does
not completely mitigate ocular GVHD symptoms. Thus,
ancillary and supportive care is needed, including the
frequent application of artiﬁcial tears or other ocular lubri-
cants, the use of occlusive eyewear, or the application of
topical immunosuppressive eye drops [11]. The efﬁcacy of
these conventional treatments is often limited once dry eye
disease is established. Lacrimal gland destruction by chronic
GVHD may be irreversible even if the immunologic attack is
halted. Scleral lenses are a recommended option for these
severe cases [11]. A case series analysis showed that the liquid
corneal bandage provided by ﬂuid-ventilated, gas-permeable
scleral lenses (prosthetic replacement of the ocular surface
ecosystem [PROSE] lenses, Boston Foundation for Sight,
Needham, MA, USA) were effective in mitigating symptoms
and resurfacing corneal erosions in the treatment of severe
ocular GVHD [12]. Many patients, however, are not able to
access PROSE lenses because of high costs and because they
live far from sites that can ﬁt PROSE lenses.
Figure 1. Consolidated Standards of Reporting Trials (CONSORT) diagram.
*Two patients who continued wearing BSCLs at 2 weeks. yAmong 3 patients
who did not answer questionnaires at 3 months, 2 continued wearing BSCLs
and 1 stopped BSCLs because of lack of improvement.
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disposable, soft contact lenses used for the treatment of a
diseased or injured cornea [13-15]. Lenses are available in
different diameters with a range of different base curves,
powered if necessary and in a variety of materials. Materials
are chosen to enhance permeability to oxygen or to reduce
surface deposition, and parameters are chosen to maximize
comfort and to enhance the ﬁtting pattern. BSCLs are much
less expensive than PROSE lenses and can be ﬁtted and
dispensed on the same day. We hypothesized that protection
of the surface of injured corneas with BSCLs would be safe
and effective in providing relief of ocular GVHD symptoms.
To test this hypothesis, we conducted a single-center, phase II
trial of BSCLs for patients with ocular GVHD who are symp-
tomatic despite conventional treatments.
METHODS
Eligibility
Patients whomet all the following criteriawere eligible: (1) age 18 years
or older, (2) diagnosis of chronic GVHD per National Institutes of Health
(NIH) criteria [10], (3) moderate to severe ocular GVHD [10], and (4) absence
of new systemic immunosuppressive medications within 1 month. Exclu-
sion criteria were absolute neutrophil count less than 1000/mL, known hy-
persensitivity or allergy to contact lens care products, treatment with scleral
lenses within the previous 3 months, and evidence of any active infection in
the eyes. The Institutional Review Board of the Fred Hutchinson Cancer
Research Center approved the study, and patients gave written consent to
participate. This study was registered at www.clinicaltrials.gov as
NCT01616056.
Study Procedure
Disposable extended-wear BSCLs (lens size 14.0 to 18.0 mm, center
thickness .05 mm, PureVision; Bausch & Lomb, Rochester, NY) were placed
for a maximum of 1 month at a time and were replaced every 2 to 4 weeks
by ophthalmologists or by the patient. PureVision is a soft silicone hydrogel
contact lens with high oxygen permeability. If the patient was not
comfortable with PureVision, thinner lenses (lens size 14.0 mm, center
thickness .038 mm, SoftLens 38; Bausch & Lomb) were prescribed. In
addition to this principle, other BSCLs (lens size 14.5 to 16.0 mm, Flexlens;
Ideal Optics, Duluth, GA, and lens size 16.0 to 22.0 mm, Kontur; Kontur
Kontact Lens, Hercules, CA) were considered based on corneal topography.
Patients were instructed to use antibiotic eye drops (oﬂoxacin, .3%
ophthalmic solution, or moxiﬂoxacin HCL .5% ophthalmic solution) 4 times a
day to prevent ocular infection. One lens costs 10 to 65 US dollars.
Endpoints
Patients completed the following standardized symptom questionnaires
at enrollment and at 2 weeks, 4 weeks, and 3 months afterward: (1) the Lee
symptom scale, a 37-item validated symptom scale for chronic GVHD that
contains a 3-item eye subscale (range, 0 to 100) [16]; (2) the ocular surface
disease index (OSDI), a 12-item validated survey that measures dry eye
symptoms (range, 0 to 100) [17]; and (3) an 11-point eye symptom rating
scale recommended by the NIH consensus conference where patients
indicate their most bothersome eye symptom and rate it on a scale from 0 to
10 [18]. Higher scores indicate worse symptoms in these measures.
All patients were surveyed at follow-up assessments even if they
stopped wearing BSCLs. Patients were assessed by ophthalmologists at
enrollment, at 2 weeks, and afterward as medically needed. The ophthal-
mology assessments included visual acuity using the logMAR chart (Early
Treatment Diabetic Retinopathy Study [ETDRS]) and slit lamp exam. A
logMAR value of 0 is equivalent to 20/20 vision on a Snellen chart. Corneal
ﬁlaments (absence or presence) and punctate epithelial erosions (none, 1þ,
2þ, 3þ, 4þ) were assessed by slit lamp examination [9].
Analysis of ophthalmology assessments was not made after 2 weeks
because of incomplete data collection. The primary endpoint was symptom
improvement by the Lee eye subscale after 2 weeks of therapy. Secondary
endpoints included improvement in the OSDI, the 11-point eye symptom
rating, and ophthalmologic assessments.
Statistical Analysis
Measurements after placement of BSCLs were compared with baseline
(enrollment) by paired t-tests. Two-sided P < .05 were considered statisti-
cally signiﬁcant. Clinically meaningful changes were calculated using a
threshold of 2 points on the 0 to 10 scale and using a half-standard deviation
for other measures [18,19]. Because a previous prospective observationalstudy [7] showed that patients with NIH eye scores of 2 or 3 had standard
deviations of 23.6 for the Lee eye subscale and 21.8 for the OSDI, clinically
meaningful changes were deﬁned as 11.8 for the Lee eye subscale and 10.9
for the OSDI. Improvement in ophthalmology assessments was deﬁned as
improvement in either eyewithout worsening in the other eye. Stability was
deﬁned as the absence of improvement or worsening in both eyes. Wors-
ening was deﬁned as worsening in either eye.Sample Size
Based on a previous observational study [7], the mean Lee eye subscale
for eye score 2 or 3 was 67.6 and that for eye score 1 was 40.9. If we hy-
pothesize that eye symptoms improve to eye score 1 or less in at least two
thirds of patients after BSCL therapy, we would expect at least an 18-point
improvement in the Lee eye subscale. Twenty patients would provide 90%
power to detect a mean change of 18 points at a 2-sided .05 level of
signiﬁcance.RESULTS
Patient Characteristics
Twenty patients consented to participate in the study
from August 2012 to September 2014 (Figure 1). One patient
was not included in the analysis because of a protocol
violation at enrollment (only 1 BSCL was placed while
awaiting a prescription lens for the second eye). The median
patient age was 55 years (range, 32 to 75). The median time
from transplantation to enrollment was 36.6 months (range,
8 to 157). All patients had mobilized blood cell trans-
plantation from an HLA-identical sibling donor (n ¼ 5; 26%),
from an HLA-matched unrelated donor (n¼ 12; 63%), or from
an HLA-mismatched unrelated donor (n ¼ 2; 11%).
Fourteen patients (74%) had moderate ocular GVHD and 5
(26%) had severe ocular GVHD at enrollment. All patients
were taking systemic immunosuppressive treatment for
chronic GVHD. The current treatment for ocular GVHD at
enrollment included artiﬁcial tears (n ¼ 19; 100%), viscous
ointment (n ¼ 11; 58%), cyclosporine eye drops (n ¼ 7; 37%),
ﬂax seed oil (n ¼ 6; 32%), punctal plugs (n ¼ 6; 32%), steroid
eye drops (n ¼ 5; 26%), occlusive eyewear (n ¼ 5; 26%),
cevimeline (n ¼ 4; 21%), autologous serum tears (n ¼ 1; 5%),
and punctal cauterization (n ¼ 1; 5%). No patient had pre-
viously used scleral lenses for treatment of ocular GVHD.
Other demographics of study participants are shown in
Table 1.
Table 1
Patient Characteristics (N ¼ 19)
Characteristic Value
Patient median age at enrollment, yr (range) 55 (32-75)
Median time from transplantation to enrollment,
mo (range)
36.6 (8-157)
Patient gender, no. (%)
Male 11 (58)
Female 8 (42)
Diagnosis at transplantation, no. (%)
Acute leukemia 7 (37)
Myelodysplastic syndrome 5 (26)
Malignant lymphoma 5 (26)
Chronic leukemia 2 (11)
Graft type, no. (%)
G-CSFemobilized blood cells 19 (100)
Donorepatient gender combination, no. (%)
Female to male 4 (21)
Other 15 (79)
HLA and donor type, no. (%)
Identical sibling 5 (26)
Matched unrelated 12 (63)
Mismatched unrelated 2 (11)
Conditioning regimen, no. (%)
Myeloablative 6 (32)
Nonmyeloablative/reduced intensity 13 (68)
NIH eye score at enrollment, no. (%)
Moderate (score 2) 14 (74)
Severe (score 3) 5 (26)
Systemic immunosuppressive treatment at enrollment, no. (%)
Prednisone 13 (68)
Sirolimus 5 (26)
Tacrolimus 4 (21)
Cyclosporine 3 (16)
Mycophenolate mofetil 2 (11)
Extracorporeal photopheresis 1 (5)
Methotrexate 1 (5)
Azathioprine 1 (5)
Nirotinib 1 (5)
Treatment for eye GVHD at enrollment, no. (%)
Artiﬁcial tears 19 (100)
Viscous ointment 11 (58)
Cyclosporine eye drop 7 (37)
Flax seed oil 6 (32)
Punctal plugs 6 (32)
Steroid eye drop 5 (26)
Occlusive eyewear 5 (26)
Cevimeline 4 (21)
Autologous serum tears 1 (5)
Punctal cauterization 1 (5)
G-CSF indicates granulocyte colony-stimulating factor.
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The mean Lee eye subscale score at enrollment was
75.4  4.25. Compared with enrollment, the mean score
improved signiﬁcantly to 63.2  4.82 at 2 weeks (P ¼ .01), to
61.8  4.52 at 4 weeks (P ¼ .005), and to 56.3  7.28 at
3 months (P ¼ .02) after placement of BSCLs (Figure 2A,D).
Two patients changed systemic treatment before 2 weeks
because of chronic GVHD activity outside the eyes (initiation
of extracorporeal photopheresis for skin GVHD and azathi-
oprine for oral GVHD, respectively), and another patient
started treatment with rituximab for worsening skin scle-
rosis and fasciitis before the 3-month assessment. Results
were similar even if these patients who changed systemic
treatment were excluded from the analysis (mean score
63.2  5.40 at 2 weeks, P ¼ .02; 62.7  4.91 at 4 weeks,
P ¼ .01; and 58.3  7.76 at 3 months, P ¼ .06).
Secondary Endpoints
The mean OSDI score at enrollment was 54.5  6.19.
Compared with enrollment, the mean score improvedsigniﬁcantly to 36.8  5.32 at 2 weeks (P ¼ .002), to
32.9  5.74 at 4 weeks (P < .001), and to 35.6  6.50 at
3 months (P ¼ .001) after placement of BSCLs (Figure 2B,E).
Results were similar even if patients who changed systemic
treatment before assessment were excluded (mean score
37.3  5.80 at 2 weeks, P ¼ .005; 32.2  6.31 at 4 weeks,
P¼ .002; and 38.17.11 at 3 months, P¼ .003). The mean 11-
point eye symptom rating at enrollment was 7.11  0.42.
Compared with enrollment, the mean score improved
signiﬁcantly to 5.00  .56 at 2 weeks (P ¼ .001), to 4.37  .45
at 4 weeks (P< .001), and to 3.94 .59 at 3 months (P< .001)
after placement of BSCLs (Figure 2C,F). Results were similar
even if patients who changed systemic treatment before
assessmentwere excluded (mean score 4.71 .55 at 2 weeks,
P < .001; 4.35  .51 at 4 weeks, P < .001; and 4.14  .66 at
3 months, P < .001).
The proportions of participants who experienced clini-
cally meaningful changes in measurements compared with
enrollment are shown in Figure 3. According to the Lee eye
subscale, clinically meaningful improvement (ie, a decreased
score of 11.8 or greater) was observed in 9 patients (47%) at
2 weeks, in 11 patients (58%) at 4 weeks, and in 9 patients
(47%) at 3 months (Figure 3A). According to OSDI scores,
clinically meaningful improvement (ie, a decreased score of
10.9 or greater) was observed in 10 patients (53%) at 2 weeks,
in 13 patients (68%) at 4 weeks, and in 10 patents (53%) at
3 months (Figure 3B). According to the 11-point eye symp-
tom ratings, clinically meaningful improvement (ie, a
decreased score of 2 or greater) was observed in 11 patients
(58%) at 2 weeks, in 13 patients (68%) at 4 weeks, and in 12
patents (63%) at 3 months (Figure 3C). Thus, 47% to 68% of
participants experienced clinically meaningful symptom
improvements with BSCL use during the 3-month study
period.
Seventeen patients returned to the ophthalmology clinic
andwere evaluated at 2 weeks after placement of BSCLs. Two
patients did not return to the clinic at 2 weeks because of
personal scheduling difﬁculties but continued using BSCLs.
The mean logMAR visual acuity at enrollment was .26  .030
in 38 eyes from 19 patients. Compared with enrollment, the
mean logMAR visual acuity improved signiﬁcantly to
.15  .030 at 2 weeks (P ¼ .005; 34 eyes; Figure 4A). Results
were similar even if the 2 patients who changed systemic
treatment before assessment were excluded (mean
.15  .032; P ¼ .004; 30 eyes).
Slit lamp exam at enrollment revealed corneal abnor-
malities in all patients, including ﬁlamentary keratitis in 20
of 38 eyes (53%) and punctate epithelial erosions in 31 of 38
eyes (82%) (grade 1, n¼ 5; grade 2, n¼ 17; grade 3, n¼ 6; and
grade 4, n ¼ 3 eyes). Based on follow-up slit lamp exam at
2 weeks (Figure 4B), ﬁlamentary keratitis remained absent in
8 patients (42%), resolved in 6 patients (32%), and remained
present in 3 patients (16%). Punctate epithelial erosions
improved in 12 patients (63%), showed stability in 4 patients
(21%), and worsened in 1 patient (5%).
Compliance of Study Treatment
At 2 weeks, 17 patients (89%) continued wearing BSCLs.
One patient stopped BSCLs because of pain, and another
patient did not wear BSCLs after they fell out. At 4 weeks, 18
patients (95%) continued wearing BSCLs. One patient
removed 1 lens because of pain. At 3months, 2 patients (11%)
stopped using BSCLs after adequate improvement in eye
symptoms and 14 patients (74%) continued wearing BSCLs.
One patient (5%) stopped wearing BSCLs because of blurred
Figure 2. Symptom measures over time. (A and D) Lee eye subscale. (B and E) Ocular surface disease index. (C and F) The 11-point eye symptom ratings. Three
patients did not complete survey at 3 months. Box-plots show median (thick horizontal line), 25 and 75 percentiles (box borders), and 5 and 95 percentiles (outer
horizontal lines). P values were derived from paired t-tests compared with baseline.
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of a lack of improvement in eye symptoms. Among patients
who continued to wear BSCLs, 17 patients (100%) at 2 weeks,
17 patients (94%) at 4 weeks, and 13 patients (93%) at
3 months reported using antibiotic drops. As of February
2015, 6 patients (32%) stopped using BSCLs after adequate
improvement in eye symptoms, and 10 patients (53%) are
continuing to wear BSCLs, with a median duration of
20 months (range, 6 to 24) without severe adverse events.
Three patients (16%) stopped wearing BSCLs because of
inadequate improvement in eye symptoms, and 1 of themFigure 3. Clinically meaningful changes in symptoms compared with baseline. (A) Le
ratings. Clinical meaningful change was deﬁned as 2 points on the 0- to 10-point scale
10.9 for OSDI based on a previous prospective observational study [7]).started PROSE lenses and had moderate improvement in
symptoms and ocular surface ﬁndings.
Adverse Events
Adverse events after starting treatment with BSCLs are
summarized in Table 2. The most frequent adverse events
with BSCL therapy included foreign body sensation (n ¼ 14;
74%), swollen eyelids (n ¼ 5; 26%), and excessive tearing
(n ¼ 2; 11%), but these were considered mild and rarely
caused patients to discontinue BSCLs. Although it was not
related to BSCL therapy, 1 patient had corneal edema ande eye subscale. (B) Ocular surface disease index. (C) The 11-point eye symptom
and a half-standard deviation for other measures (11.8 for Lee eye subscale and
Figure 4. Ophthalmologic assessment at 2 weeks. (A) Visual acuity. (B) Corneal changes assessed by slit lamp exam. P values were derived from paired t-tests
compared with baseline.
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prophylaxis with systemic acyclovir. The patient was treated
with triﬂuridine eye drops, and lesions resolved during
continued BSCL wear. No corneal ulceration or ocular infec-
tion related to the use of BSCLs was documented.DISCUSSION
Ocular involvement is 1 of the most frequent manifesta-
tions of chronic GVHD after allogeneic hematopoietic cell
transplantation [3,5,7]. The pathogenesis is thought to
involve dysfunction of conjunctiva and lacrimal glands
caused by inﬂammation, resulting in tear deﬁciency and
severe damage to the ocular surface (ie, keratoconjunctivitis
sicca) [4,6,9,20]. Participants in our study had signiﬁcant
symptoms and ocular surface abnormalities despite con-
ventional treatments such as artiﬁcial tears, viscous oint-
ment, cyclosporine eye drops, punctal plugs, and steroid eye
drops in addition to systemic immunosuppressive treatment.
Our results showed that BSCL therapy for such patients
provided prompt improvement in symptoms, visual acuity,
and corneal integrity in approximately 50% of patients. The
results of this trial suggest that many patients who are not
able to access PROSE lenses, because of cost, time, and the
temporary relocation required to ﬁt PROSE lenses, may
beneﬁt from BSCLs.
We used eye symptoms as the primary endpoint in this
study, because BSCLs were not expected to reverse ocular
GVHD or the lacrimal damage. Before placement of the
BSCLs, participants reported a high symptom burden
from ocular GVHD. We used 2 standardized and validated
symptom measures recommended by the NIH consensus
for assessing response of ocular GVHD as well as a validated
measure for dry eye disease [7,18]; all measures showed sta-
tistically signiﬁcant and clinically meaningful improvementTable 2
Adverse Events during the Study Period
Event No. (%)
Foreign body sensation 14 (74)
Swollen eye lids 5 (26)
Excessive tearing 2 (11)
Corneal edema and stromal haze 1 (5)
Ocular infection 0 (0)in symptoms after placement of BSCLs. Furthermore, visual
acuity and corneal ﬁndings as measured by slit lamp exam
were improved after 2 weeks of therapy. Improvement in
visual acuity was also reported in a case series of 7 patients
who were treated with silicone hydrogel soft contact
lenses for ocular GVHD [21].
Therapeutic use of BSCLs for ocular surface diseases re-
lieves pain, stabilizes wounds, and helps corneal epithelial
healing, although extended wear may cause adverse events
such as corneal edema, stromal inﬁltrates, neo-
vascularization, and, most seriously, microbial keratitis
[22,23]. Although initial studies of BSCLs for ocular surface
disorders showed no episodes of microbial keratitis [21,24],
this complication has been reported particularly among pa-
tients who used lenses overnight in larger subsequent
studies [25,26]. A study showed that the use of prophylactic
antibiotic drops did not eliminate the risk of microbial
keratitis in patients with chronic ocular surface disease
treated with BSCLs [27]. Although microbial keratitis or
serious complications were not observed in GVHD patients in
the current study or in a prior case series [21], larger studies
are warranted to determine the risk of ocular infection in this
population.
This study has some limitations. First, we did not evaluate
tear ﬁlm, because BSCLs were not anticipated to affect this
parameter based on a previous case series showing no
changes in tear breakup time after using BSCLs [21]. Second,
long-term safety and efﬁcacy remain to be determined. Only
2 participants were able to stop BSCL therapy after 3 months
after sustained adequate improvement, and 11 participants
continued wearing BSCLs for more than 1 year, suggesting
that many patients will need longer treatment. Third, we
excluded children and thus cannot provide any safety and
efﬁcacy data on this population, although we believe BSCLs
should be studied in children. Finally, this study enrolled a
relatively small number of patients at a single center. A larger
multicenter study is warranted to conﬁrm these promising
results.
BSCLs are a safe, tolerable, and effective treatment option
that improves manifestations of moderate to severe ocular
GVHD in approximately 50% of patients who are symptom-
atic despite conventional treatments. It would be appro-
priate to have transplant physicians perform long-term
follow-up of BSCLs once stability in symptoms and safety are
Y. Inamoto et al. / Biol Blood Marrow Transplant 21 (2015) 2002e2007 2007conﬁrmed, although this needs to be individualized based on
patients’ reliability. Patients need to be evaluated annually by
ophthalmologists as part of long-term follow-up after
transplantation. Because BSCLs are widely available and do
not require a high initial expense or time commitment, they
could be used as the initial protective lenses for patients with
ocular GVHD.
ACKNOWLEDGMENTS
Financial disclosure: Supported by grant U54 CA163438
from the NIH. The Chronic GVHD Consortium (U54
CA163438) is a part of the National Center for Advancing
Translational Sciences (NCATS) Rare Diseases Clinical
Research Network, which is an initiative of the Ofﬁce of Rare
Diseases Research (ORDR), NCATS, funded through a collab-
oration between NCATS, and the National Cancer Institute.
This work was also supported by JSPS KAKENHI grant no.
15K19563 and Friends of Leukemia Research Fund.
Conﬂict of interest statement: There are no conﬂicts of in-
terest to report.
Authorship statement: Y.I., T.T.S., and S.J.L. designed the
study. Y.I., X.C., and B.E.S. performed the statistical analysis.
M.E.D.F., P.A.C., P.J.M., and T.T.S. provided patients. Y.I., Y.-C.S.,
P.L., R.W., and S.J.L. collected data. All authors wrote and
critically revised the manuscript for important intellectual
content and approved the manuscript to be published.
REFERENCES
1. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol
Blood Marrow Transplant. 2003;9:215-233.
2. Franklin RM, Kenyon KR, Tutschka PJ, et al. Ocular manifestations of
graft-vs-host disease. Ophthalmology. 1983;90:4-13.
3. Tichelli A, Duell T, Weiss M, et al. Late-onset keratoconjunctivitis sicca
syndrome after bone marrow transplantation: incidence and risk fac-
tors. European Group or Blood and Marrow Transplantation (EBMT)
Working Party on Late Effects. Bone Marrow Transplant. 1996;17:
1105-1111.
4. Ogawa Y, Okamoto S, Wakui M, et al. Dry eye after haematopoietic
stem cell transplantation. Br J Ophthalmol. 1999;83:1125-1130.
5. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-
versus-host disease after transplantation of peripheral blood stem cells
versus bone marrow in allogeneic recipients: long-term follow-up of a
randomized trial. Blood. 2002;100:415-419.
6. Kim SK. Update on ocular graft versus host disease. Curr Opin Oph-
thalmol. 2006;17:344-348.
7. Inamoto Y, Chai X, Kurland BF, et al. Validation of measurement scales
in ocular graft-versus-host disease. Ophthalmology. 2012;119:487-493.
8. Dietrich-Ntoukas T, Cursiefen C, Westekemper H, et al. Diagnosis and
treatment of ocular chronic graft-versus-host disease: report from the
German-Austrian-Swiss Consensus Conference on Clinical Practice in
chronic GVHD. Cornea. 2012;31:299-310.
9. Ogawa Y, Kim SK, Dana R, et al. International Chronic Ocular Graft-vs-
Host-Disease (GVHD) Consensus Group: proposed diagnostic criteria
for chronic GVHD (Part I). Sci Rep. 2013;3:3419.10. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of
Health consensus development project on criteria for clinical trials
in chronic graft-versus-host disease. I. Diagnosis and staging
working group report. Biol Blood Marrow Transplant. 2005;11:
945-956.
11. Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and sup-
portive care of chronic graft-versus-host disease: National Institutes of
Health consensus development project on criteria for clinical trials in
chronic graft-versus-host disease. V. Ancillary Therapy and Supportive
Care Working Group Report. Biol Blood Marrow Transplant. 2006;12:
375-396.
12. Takahide K, Parker PM, Wu M, et al. Use of ﬂuid-ventilated, gas-
permeable scleral lens for management of severe keratoconjunctivitis
sicca secondary to chronic graft-versus-host disease. Biol Blood Marrow
Transplant. 2007;13:1016-1021.
13. Donnenfeld ED, Selkin BA, Perry HD, et al. Controlled evaluation of a
bandage contact lens and a topical nonsteroidal anti-inﬂammatory
drug in treating traumatic corneal abrasions. Ophthalmology. 1995;
102:979-984.
14. Oskouee SJ, Amuzadeh J, Rajabi MT. Bandage contact lens and topical
indomethacin for treating persistent corneal epithelial defects after
vitreoretinal surgery. Cornea. 2007;26:1178-1181.
15. Blackmore SJ. The use of contact lenses in the treatment of
persistent epithelial defects. Cont Lens Anterior Eye. 2010;33:
239-244.
16. Lee S, Cook EF, Soiffer R, Antin JH. Development and validation of a
scale to measure symptoms of chronic graft-versus-host disease. Biol
Blood Marrow Transplant. 2002;8:444-452.
17. Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and val-
idity of the ocular surface disease index. Arch Ophthalmol. 2000;118:
615-621.
18. Pavletic SZ, Martin P, Lee SJ, et al. Measuring therapeutic response in
chronic graft-versus-host disease: National Institutes of Health
consensus development project on criteria for clinical trials in chronic
graft-versus-host disease. IV. Response Criteria Working Group report.
Biol Blood Marrow Transplant. 2006;12:252-266.
19. Osoba D, Rodrigues G, Myles J, et al. Interpreting the signiﬁcance of
changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:
139-144.
20. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host
syndrome in man. A long-term clinicopathologic study of 20 Seattle
patients. Am J Med. 1980;69:204-217.
21. Russo PA, Bouchard CS, Galasso JM. Extended-wear silicone hydrogel
soft contact lenses in the management of moderate to severe dry eye
signs and symptoms secondary to graft-versus-host disease. Eye Con-
tact Lens. 2007;33:144-147.
22. Poggio EC, Glynn RJ, Schein OD, et al. The incidence of ulcerative
keratitis among users of daily-wear and extended-wear soft contact
lenses. N Engl J Med. 1989;321:779-783.
23. Sankaridurg PR, Sweeney DF, Sharma S, et al. Adverse events with
extended wear of disposable hydrogels: results for the ﬁrst 13 months
of lens wear. Ophthalmology. 1999;106:1671-1680.
24. Kanpolat A, Ucakhan OO. Therapeutic use of Focus Night & Day contact
lenses. Cornea. 2003;22:726-734.
25. Schein OD, McNally JJ, Katz J, et al. The incidence of microbial keratitis
among wearers of a 30-day silicone hydrogel extended-wear contact
lens. Ophthalmology. 2005;112:2172-2179.
26. Stapleton F, Edwards K, Keay L, et al. Risk factors for moderate and
severe microbial keratitis in daily wear contact lens users. Ophthal-
mology. 2012;119:1516-1521.
27. Saini A, Rapuano CJ, Laibson PR, et al. Episodes of microbial keratitis
with therapeutic silicone hydrogel bandage soft contact lenses. Eye
Contact Lens. 2013;39:324-328.
